

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

or

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number **333-255266**

UPEXI, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of
incorporation or organization)

83-3378978

(IRS Employer
Identification No.)

3030 North Rocky Point Drive
Tampa, FL

(Address of principal executive offices)

33607

(Zip Code)

(701) 353-5425

(Registrant's telephone number, including area code)

(Former name, former address, and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	UPXI	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated Filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES NO

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

As of November 17, 2023, the registrant had 20,306,870 shares of common stock, par value \$0.001 per share, outstanding.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION

<u>Item 1.</u>	<u>Interim Condensed Consolidated Financial Statements</u>	4
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	28
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	33
<u>Item 4.</u>	<u>Controls and Procedures</u>	33

PART II - OTHER INFORMATION

<u>Item 1.</u>	<u>Legal Proceedings</u>	35
<u>Item 1A.</u>	<u>Risk Factors</u>	35
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	35
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	35
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	35
<u>Item 5.</u>	<u>Other Information</u>	35
<u>Item 6.</u>	<u>Exhibits</u>	36
<u>SIGNATURES</u>		37

[Table of Contents](#)

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "potential" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, such as the COVID-19 outbreak and associated business disruptions including delayed clinical trials and laboratory resources, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.

Our unaudited condensed financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to "common shares" refer to shares of our common stock.

As used in this quarterly report, the terms "we", "us", "our" and "our company" mean Upexi, Inc., unless otherwise indicated.

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

UPEXI, INC.

**Interim Unaudited Condensed Consolidated Financial Statements
For the Three Month Periods Ended September 30, 2023 and 2022**

	Page
Condensed Consolidated Balance Sheets as of September 30, 2023 and June 30, 2023 (Unaudited)	5
Condensed Consolidated Statements of Operations for the Three Months Ended September 30, 2023 and 2022 (Unaudited)	6
Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended September 30, 2023 and 2022 (Unaudited)	7
Condensed Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2023 and 2022 (Unaudited)	8
Notes to the Unaudited Condensed Consolidated Financial Statements	9

[Table of Contents](#)

UPEXI, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	September 30, 2023	June 30, 2023
ASSETS		
Current assets		
Cash	\$ 417,108	\$ 4,492,291
Accounts receivable	9,756,622	7,163,564
Inventory	13,786,262	11,557,128
Due from Bloomios	-	845,443
Prepaid expenses and other receivables	957,584	1,307,299
Current assets of discontinued operations	-	89,989
Total current assets	<u>24,917,576</u>	<u>25,455,714</u>
Property and equipment, net	7,744,874	7,526,463
Intangible assets, net	12,385,139	13,571,960
Goodwill	11,719,155	10,251,281
Deferred tax asset	6,076,423	5,604,056
Other assets	365,060	96,728
Assets held for sale	-	936,054
Right-of-use asset	2,037,515	410,811
Total other assets	40,328,166	38,397,353
Total assets	<u>\$ 65,245,742</u>	<u>\$ 63,853,067</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable	\$ 4,638,195	\$ 3,969,746
Accrued compensation	513,934	533,842
Deferred revenue	153,769	-
Accrued liabilities	3,883,842	3,365,562
Acquisition payable	300,000	-
Current portion of notes payable	4,255,357	1,302,021

Current portion of convertible notes payable	-	1,254,167
Current portion of acquisition note payable	5,656,620	5,656,620
Current portion of related party note payable	-	1,429,356
Line of Credit	118,001	882,845
Current portion of operating lease payable	517,099	419,443
Current liabilities of discontinued operations	-	792,408
Total current liabilities	20,036,817	19,606,010
Operating lease payable, net of current portion	1,600,489	163,359
Related party note payable	1,444,493	-
Convertible notes payable	2,150,000	895,833
Acquisition notes payable, net of current	7,968,497	7,605,085
Notes payable, net of current portion	4,475,450	7,746,157
Total long-term liabilities	17,638,929	16,410,434
Commitments and contingencies		
Stockholders' equity		
Preferred stock, \$0.001 par value, 100,000,000 shares authorized, and 500,000 and 500,000 shares issued and outstanding, respectively	500	500
Common stock, \$0.001 par value, 100,000,000 shares authorized, and 20,306,870 and 16,713,345 shares issued and outstanding, respectively	20,307	20,216
Additional paid in capital	52,106,752	51,522,229
Accumulated deficit	(24,557,563)	(23,201,175)
Total stockholders' equity attributable to Upexi, Inc.	27,569,996	28,341,770
Non-controlling interest in subsidiary		(505,147)
Total stockholders' equity	27,569,996	27,836,623
Total liabilities and stockholders' equity	\$ 65,245,742	\$ 63,853,067

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[Table of Contents](#)

UPEXI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended September 30,	
	2023	2022
Revenue		
Revenue	\$ 27,347,642	\$ 11,218,799
Cost of Revenue	18,639,793	5,401,316
Gross profit	<u>8,707,849</u>	<u>5,817,483</u>
Operating expenses		
Sales and marketing	2,848,667	1,727,469
Distribution costs	2,850,616	2,487,834
General and administrative expenses	2,255,928	2,127,846
Share-based compensation	421,887	927,326
Amortization of acquired intangible assets	1,186,821	729,909
Depreciation	286,084	194,497
	<u>9,850,003</u>	<u>8,194,881</u>
Loss from operations	(1,142,154)	(2,377,398)
Other expense (income), net		
Change in derivative liability	-	(1,770)
Interest expense, net	<u>874,185</u>	<u>433,478</u>

Other expense (income), net	874,185	431,708
Loss from operations before income tax	(2,016,339)	(2,809,106)
Gain (Loss) from the sale of Interactive Offers	380,624	-
(Loss) income from discontinued operations	(193,040)	(644,615)
Income tax benefit	472,367	708,201
Net (loss) income	(1,356,388)	(2,745,520)
Net loss attributable to noncontrolling interest	-	148,005
Net (loss) income attributable to Upexi, Inc.	\$ (1,356,388)	\$ (2,597,515)
Basic and Diluted loss per share:		
(Loss) income per share from continuing operations	\$ (0.07)	\$ (0.16)
(Loss) income per share from discontinued operations	\$ (0.01)	\$ (0.04)
Total (loss) income per share	\$ (0.07)	\$ (0.16)
Basic weighted average shares outstanding	20,244,618	16,713,345
Fully diluted weighted average shares outstanding	20,244,618	16,713,345

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[Table of Contents](#)

UPEXI, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

	Preferred Stock Shares	Preferred Stock Par	Common Stock Shares	Common Stock Par	Additional Paid In Capital	Accumulated Deficit	Non-controlling Interest	Total Shareholders' Equity
2022								
Balance, June 30, 2022	500,000	\$ 500	16,713,345	\$ 16,713	\$34,985,597	\$ (6,270,886)	\$ 54,820	\$ 28,786,744
Stock based compensation	-	-	-	-	927,326	-	-	927,326
Amortization of common stock issuance for services	-	-	-	-	70,350	-	-	70,350
Net income for the three months ended September 30, 2022	-	-	-	-	-	(2,597,515)	(148,005)	(2,745,520)
Balance, September 30, 2022	<u>500,000</u>	<u>\$ 500</u>	<u>16,713,345</u>	<u>\$ 16,713</u>	<u>\$35,983,273</u>	<u>\$ (8,868,401)</u>	<u>\$ (93,185)</u>	<u>\$ 27,038,900</u>

2023

Balance, June 30, 2023	500,000	\$ 500	20,215,961	\$ 20,216	\$51,522,229	\$ (23,201,175)	\$ (505,147)	\$ 27,836,623
Issuance of stock and equity for purchase of Cygnet			90,909	91	162,636		505,147	667,874
Stock based compensation	-	-	-	-	421,887	-	-	421,887
Net loss for the three months ended September 30, 2023	-	-	-	-	-	(1,356,388)	-	(1,356,388)
Balance, September 30, 2023	<u>500,000</u>	<u>\$ 500</u>	<u>20,306,870</u>	<u>\$ 20,307</u>	<u>\$52,106,752</u>	<u>\$ (24,557,563)</u>	<u>\$ -</u>	<u>\$ 27,569,996</u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[Table of Contents](#)

**UPEXI, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

	Three Month's Ended September 30,	
	2023	2022
Cash flows from operating activities		
Net loss from operations		
	\$ (1,356,388)	\$ (2,745,520)
Adjustments to reconcile net (loss) income from continuing operations to net cash (used) provided by operating activities:		
Depreciation and amortization	1,472,905	924,406
Amortization of loan costs	15,137	49,158
Amortization of consideration discount	(108,955)	-
Change in deferred tax asset	-	(729,483)

Change in derivative liability	-	1,770
Stock based compensation	421,887	927,326
Changes in assets and liabilities, net of acquired amounts		
Accounts receivable	(2,435,858)	(180,525)
Inventory	(1,138,306)	(912,492)
Prepaid expenses and other assets	257,797	(681,964)
Accounts payable and accrued liabilities	690,004	969,770
Accrued liabilities related to acquisition	-	(139,233)
Deferred revenue	19,819	-
Net cash used by operating activities - Continuing Operations	(2,120,290)	(2,516,787)
Net cash (used) provided by operating activities - Discontinued Operations	(223,957)	(4,240)
Net cash (used) provided by operating activities	(2,344,247)	(2,521,027)
Cash flows from investing activities		
Proceeds from the sale of Interactive Offers, net of liabilities paid	147,592	-
Acquisition of Lucky Tail	-	(2,000,000)
Acquisition of VitaMedica, Inc., net of cash acquired	-	(500,000)
Acquisition of Cygnet, Inc., net of cash acquired	(500,000)	-
Acquisition of property and equipment	(296,313)	(147,930)
Net cash used in investing activities - Continuing Operations	(648,721)	(2,647,930)
Net cash used in investing activities - Discontinued Operations	-	-
Net cash used in investing activities	(648,721)	(2,647,930)
Cash flows from financing activities		
Repayment of related party note payable	-	1,470,000
Payment of note payable	(317,371)	(152,186)
Change in line of credit, net	(764,844)	-
Net cash provided (used) by financing activities - Continuing Operations	(1,082,215)	1,317,814
Net cash provided by financing activities - Discontinued Operations	-	-
Net cash provided (used) by financing activities	(1,082,215)	1,317,814
Net decrease in cash - Continuing Operations	(3,851,226)	(3,846,903)
Net (decrease) increase in cash - Discontinued Operations	(223,957)	(4,240)
Cash, beginning of period	4,492,291	7,149,806
Cash, end of period	<u>\$ 417,108</u>	<u>\$ 3,298,663</u>
Supplemental cash flow disclosures		
Interest paid	\$ 94,860	\$ 239,117
Income tax paid	\$ -	\$ -
Issuance of common stock for acquisition of Cygnet	\$ 162,727	\$ -
Issuance of debt for the acquisition payable for Cygnet	\$ 300,000	\$ -
Bloomios non-cash payment of receivable, net	\$ 845,443	\$ -
Stock issued for construction services for property and equipment	\$ -	\$ 70,350

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[Table of Contents](#)

UPEXI, INC.
Notes to Unaudited Condensed Consolidated Financial Statements

Note 1. Background Information

Upexi is a multi-faceted brand owner with established brands in health, wellness, pet, beauty and other growing markets. We operate in emerging industries with high growth trends and look to drive organic growth of our current brands. We focus on direct to consumer and Amazon brands that are scalable and have anticipated, high industry growth trends. Our goal is to continue to accumulate consumer data and build out a significant customer database across all industries we sell into. The growth of our current customer database has been key to the year-over-year gains in sales and profits. To drive additional growth, we have and will continue to acquire profitable Amazon and eCommerce businesses that can scale quickly and reduce costs through corporate synergies. We utilize our in-house SaaS programmatic ad technology to help achieve a lower cost per acquisition and accumulate consumer data for increased cross-selling between our growing portfolio of brands.

Upexi, Inc. (the "Company") is a Nevada corporation with fourteen active subsidiaries through which the Company primarily conducts its business. The Company's fourteen active subsidiaries are as follows:

- HAVZ, LLC, d/b/a/ Steam Wholesale, a California limited liability company
 - SWCH, LLC, a Delaware limited liability company
 - Cresco Management, LLC, a California limited liability company
- Trunano Labs, Inc., a Nevada corporation
- MW Products, Inc., a Nevada corporation
- Upexi Holding, LLC, a Delaware limited liability company
 - Upexi Pet Products, LLC, a Delaware limited liability company
- VitaMedica, Inc., a Nevada corporation
- Upexi Enterprise, LLC, a Delaware limited liability company
 - Upexi Property & Assets, LLC, a Delaware limited liability company
 - Upexi 17129 Florida, LLC, a Delaware limited liability company
 - E-Core Technology, Inc.
 - Upexi Distribution Management LLC, a Delaware limited liability company
- Cygnet Online, LLC ("Cygnet"), a Delaware limited liability company.

In addition, the Company has four wholly owned subsidiaries that had no activity during the three months ended September 30, 2023 and September 30, 2022, respectively.

- Steam Distribution, LLC, a California limited liability company
- One Hit Wonder, Inc., a California corporation
- One Hit Wonder Holdings, LLC, a California limited liability company
- Vape Estate, Inc., a Nevada Corporation

Our products are distributed in the United States of America and internationally through multiple entities and managed through our locations in Florida, California, and Nevada.

Upexi operates from our corporate location in Tampa, Florida where direct to consumer and Amazon sales are driven by on-site and remote teams for all brands. The Tampa location also supports all the other locations with accounting, corporate oversight, day-to-day finances, business development and operational management operating from this location.

VitaMedica operates mainly from our California location with product development and day to day management with the primary fulfillment center located

in Tampa Florida.

Cygnet Online operates from our South Florida location with a full on-site GMP warehouse and distribution center, day-to-day operations of our Amazon liquidation business team from this location with support of remote team members.

Lucky Tail operates from our Clearwater, Florida location with sales and marketing driven by on-site and remote teams that operate the Amazon sales strategy and daily business operations.

HAVZ, LLC, d/b/a/ Steam Wholesale operates manufacturing and/or distribution centers in Henderson, Nevada supporting our health and wellness products, including those products manufactured with hemp ingredients and our overall distribution operations. We have continued to manage these operations with corporate focus on larger opportunities that have warranted the majority of corporate focus and investments for the future.

[Table of Contents](#)

Business Acquisitions

On April 1, 2022, the Company entered into a securities purchase agreement with a single investor to acquire 55% of the equity interest in Cygnet Online, LLC, a Delaware limited liability corporation. The agreement also enables the Company to purchase the remaining 45% over the following two years. On September 1, 2023, the Company purchased the remaining 45% of Cygnet Online, LLC for \$500,000 cash, 90,909 shares of the Company's common stock and a \$300,000 cash payment due on September 1, 2024.

On August 12, 2022, the Company entered into an asset purchase agreement with GA Solutions, LLC, a Delaware limited liability company ("LuckyTail"), pursuant to which the Company acquired substantially all of the assets of LuckyTail. LuckyTail sells pet nail grinders and other pet products through various sales channels including some international sales channels.

On October 31, 2022, the Company and its wholly owned subsidiary Upexi Enterprise, LLC, entered into a securities purchase agreement to purchase the outstanding stock of E-Core Technology, Inc. d/b/a New England Technology, Inc. ("E-Core"), a Florida corporation. E-Core distributes non-owned branded products to national retail distributors and has branded products in the toy industry that E-core sells direct to consumers through online sales channels and sells to national retail distributors.

Business Divested

On October 26, 2022, the Company entered into a membership interest purchase agreement to sell 100% of the membership interests of Infusionz LLC, a Colorado limited liability company ("Infusionz"), included in the sale was all of the rights to Infusionz brands and the manufacturing of certain private label business. Infusionz was originally purchased by the Company in July of 2020. The divestiture of Infusionz and related private label manufacturing represents a strategic shift in our operations and will allow us to become a predominantly product distribution focused company for both our Company owned brands and non-owned brands. As a result, the results of the business were classified as discontinued operations in our condensed statements of operations and excluded from both continuing operations and segment results for all periods presented.

On August 31, 2023, Upexi, Inc. (the "Company") entered into an Equity Interest Purchase Agreement ("EIPA") pursuant to which the Company sold one hundred percent (100%) of the issued and outstanding equity (the "Interests") of its wholly owned subsidiary Interactive Offers, LLC ("Interactive") to Amplifyir Inc. (the "Buyer"). The purchase price for the Interests was One Million Two Hundred Fifty Thousand Dollars (\$1,250,000), subject to certain customary post-closing adjustments. In addition, the Buyer is obligated to pay the Company two-and one- half percent (2.5%) of certain advertising revenues of Interactive for a two-year period post-closing. Accordingly, the results of the business were classified as discontinued operations in our statements of operations and excluded from both continuing operations and segment results for all periods presented.

Basis of Presentation and Principles of Consolidation

The Company's condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States ("GAAP"). The condensed consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of September 30, 2023 and June 30, 2023.

In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated in consolidation. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.

[Table of Contents](#)

Discontinued Operations

A discontinued operation is a component of an entity that has either been disposed of or that is classified as held for sale, which represents a separate major line of business or geographic area of options and is part of a single coordinated plan to dispose of a separate line of business or geographical area of operations. In accordance with the rules regarding the presentation of discontinued operations, the assets, liabilities, and activity of Infusionz and certain manufacturing business has been reclassified as discontinued operations for all periods presented.

Fair Value of Financial Instruments

ASC Topic 820, *Fair Value Measurement* (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguished between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumption about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

ASC 820 identified fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 established a three-tier fair value hierarchy that distinguishes between the following:

Level 1—Quoted market prices (unadjusted) in active markets for identical assets or liabilities.

Level 2—Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.

Level 3—Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value

measurement.

The carrying amounts reflected in the balance sheets for cash and cash equivalents, prepaid expenses, other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature.

Reclassification

Certain reclassifications have been made to the condensed consolidated financial statements as of and for the three months ended September 30, 2023, and for the three month period ended September 30, 2022 to conform to the presentation as of and for the three months ended September 30, 2023.

Note 2. Acquisitions

Cyngnet Online, LLC

The Company acquired 55% of Cyngnet Online, LLC, on April 1, 2022. The purchase price was \$ 5,515,756, as amended.

The following table summarizes the consideration transferred to acquire Interactive and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

[Table of Contents](#)

Fair value of consideration transferred:

Cash	\$ 1,500,000
Convertible note payable, convertible at \$6.00 per common share	1,050,000
Earnout payment	-
Common stock, 555,489 shares valued at \$5.34 per common share, the closing price on April 1, 2022.	2,965,756
	\$ 5,515,756

Recognized amounts of identifiable assets acquired and liabilities assumed:

Cash	\$ 471,237
Accounts receivable	860,882
Inventory	2,337,208
Prepaid expenses	6,900
Property and equipment	7,602
Right to use asset	410,365
Other asset	6,545
Online sales channels	1,800,000

Vendor relationships	6,000,000
Accrued liabilities	(701,606)
Notes payable	(7,298,353)
Operating lease	(422,479)
Total identifiable net assets	\$ 3,478,301
Goodwill	\$ 2,037,455

55% of the business was acquired through a stock purchase agreement on April 1, 2022. The purchase agreement provided for an increase in the purchase price of up to \$700,000 based on the attainment of certain sales threshold in the first year. Our management believed that the attainment of those sales threshold at the time of acquisition was unlikely and valued the contingency at \$0. The sales thresholds were not met, and no consideration was recorded for the contingency. The equity interest purchase agreement has standard provisions to adjust the purchase price based on the final working capital transferred to the Company. The purchase price was decreased by \$950,000 and was repaid to the Company with the reduction in the loan to the seller. The 55% purchase price allocation is final and is no longer subject to change.

The Company's consolidated financial statements for the three months ended September 30, 2023 and 2022, include the actual results of Cygnet.

On September 1, 2023, the Company completed the acquisition of the remaining 45% interest for structured cash payments equaling \$ 800,000 and 90,909 shares of the Company's common stock valued at \$ 162,727.

Fair value of consideration transferred:

Cash	\$ 800,000
Noncontrolling interest	505,147
Common stock, 90,909 shares valued at \$1.79 per common share, the closing price on September 1, 2023.	162,727
	\$ 1,467,874

Table of Contents

The additional consideration was recorded as goodwill by management and will be subject to change based on the final purchase price allocation.

The acquisition of Cygnet provided the Company with the opportunity to expand its operations as an Amazon and eCommerce seller. The resulting combination increased Cygnet's product offerings through the Company's distributors and partnerships as it continues to focus on over-the-counter supplements and beauty products. Cygnet will be the anchor company for Upexi's Amazon strategy. These are the factors of goodwill recognized in the acquisition.

LuckyTail

On August 13, 2022, the Company acquired the pet product brand and the rights to the products of LuckyTail from GA Solutions, LLC.

The following table summarizes the consideration transferred to acquire LuckyTail and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$ 2,000,000
Cash payment, 90 days after close	484,729
Cash payment, 180 days after close	469,924
Contingent consideration	112,685
Cash payment, working capital adjustment	460,901
	<u>\$ 3,528,239</u>

Recognized amounts of identifiable assets acquired, and liabilities assumed:

Inventory	\$ 460,901
Trade name	383,792
Customer list	1,834,692
Total identifiable net assets	\$ 2,679,385
Goodwill	\$ 848,854

The business was acquired through an asset purchase agreement, that acquired all elements of the business, including all of the tangible and intangible assets of the LuckyTail business. The purchase agreement provided for an increase in the purchase price based on the attainment of certain sales thresholds in the first six months. The Company estimated the value of this at approximately \$150,000 at the time of purchase. The sales calculated to a \$112,685 payout and the purchase price was adjusted. The asset purchase agreement has standard provisions to adjust the purchase price based on the final working capital transferred to the Company. The purchase price was increased by \$460,901 for the excess working capital that was transferred in the business and the final purchase price allocation was completed by an independent consulting firm and is no longer subject to change.

The Company's consolidated financial statements for the three months ended September 30, 2023, include the actual results of LuckyTail. The consolidated financial statements for the three months ended September 30, 2022, include the actual results of LuckyTail from August 13, 2022 through September 30, 2022. The Company recorded interest on the consideration of \$63,282 during the year ended June 30, 2023.

The acquisition of LuckyTail provided the Company with a foothold in the pet care industry and a strong presence on Amazon and its eCommerce store, offering nutritional and grooming products domestically and internationally. The acquisition provided both top line growth and improved EBITDA for the Company. These are the factors of goodwill recognized in the acquisition.

[Table of Contents](#)

E-Core, Technology Inc. and its subsidiaries

On October 21, 2022, the Company acquired E-Core Technology, Inc. ("E-Core") d/b/a New England Technology, Inc., a Florida corporation ("New England Technology").

The following table summarizes the consideration transferred to acquire E-Core and the amount of identified assets acquired, and liabilities assumed at the acquisition date.

Fair value of consideration transferred:

Cash	\$ 100,000
Cash payment, 120 days	3,000,000
Note payable	5,189,718
Note payable 2	4,684,029
Convertible note payable, convertible at \$4.81 per common share	2,418,860
Common stock, 1,247,402 shares valued at \$4.81 per common share, the calculated closing price on October 21, 2022.	6,000,000
	\$ 21,039,765

Recognized amounts of identifiable assets acquired, and liabilities assumed:

Cash	\$ 1,014,610
Accounts receivable	6,699,945
Inventory	7,750,011
Prepaid expenses	75,721
Trade name	1,727,249
Customer relationships	5,080,305
Accrued liabilities	(192,051)
Line of credit	(7,201,079)
Total identifiable net assets	\$ 14,635,673
Goodwill	\$ 6,404,092

The business was acquired through a membership interest purchase agreement on October 21, 2022. There was no contingent consideration payable under the asset purchase agreement, although a provision was used to adjust the purchase price based on the final working capital transferred to the Company. The purchase price was decreased by \$33,803, net and was repaid to the Company with an adjustment to the \$ 3,000,000 cash payment. The final purchase price allocation was completed by an independent consulting firm and is no longer subject to change.

The Company's consolidated financial statements for the three months ended September 30, 2023, include the actual results of E-Core. The Company recorded interest on the consideration of \$969,098 during the year ended June 30, 2023. At June 30, 2023 there was \$ 1,738,295 of unamortized debt discount that will be expensed over the next two years.

The acquisition of E-Core provided the Company with an entrance into the children's toy sector as well as national retail distribution for owned and non-owned branded products. The acquisition expands the Company's ability to leverage direct-to-consumer distribution and further develops the broad distribution capabilities of E-Core. These are the factors of goodwill recognized in the acquisition.

Revenue from acquisitions included in the financial statements.

	Three months ended September 30,	
	2023	2022
Cygnet	4,669,367	7,247,519
LuckyTail	802,504	824,775
E-Core	17,092,372	-
	<hr/> <u>\$ 22,564,243</u>	<hr/> <u>\$ 8,072,294</u>

Consolidated pro-forma unaudited financial statements.

The following unaudited pro forma combined financial information is based on the historical financial statements of the Company, LuckyTail and E-Core after giving effect to the Company's acquisitions as if the acquisitions occurred on July 1, 2022.

The following unaudited pro forma information does not purport to present what the Company's actual results would have been had the acquisitions occurred on July 1, 2022, nor is the financial information indicative of the results of future operations. The following table represents the unaudited consolidated pro forma results of operations for the three months ended September 30, 2022, as if the acquisitions occurred on July 1, 2022. The results of operations for VitaMedica, Interactive and Cygnet are included in the three months ended September 30, 2022 and the results of operations for LuckyTail are included from August 13, 2022 to September 30, 2022.

[Table of Contents](#)

Operating expenses for the three months ended September 30, 2022 have been increased for the amortization expense associated with the fair value adjustment of definite lived intangible assets of LuckyTail and E-Core by approximately \$44,619, and \$134,625, per month respectively and \$ 363,415 of interest expense.

Pro Forma, Unaudited

Three months ended September 30, 2022

	<u>Upxi, Inc.</u>	<u>LuckyTail</u>	<u>E-Core</u>	<u>Proforma Adjustments</u>	<u>Proforma</u>
Net sales	\$ 11,218,799	\$ 892,270	\$ 9,420,927	\$ -	\$ 21,531,996
Cost of sales	\$ 5,501,316	\$ 137,088	\$ 8,208,282	\$ -	\$ 13,746,686
Operating expenses	\$ 8,194,881	\$ 383,476	\$ 635,608	\$ 834,219	\$ 10,048,184
Net income (loss) from continuing operations	\$ (2,745,520)	\$ -	\$ 578,037	\$ (834,219)	\$ (2,629,996)
Basic income (loss) per common share	\$ (0.16)	\$ -	\$ 0.46	\$ -	\$ (0.15)
Weighted average shares outstanding	16,713,345		1,247,403		17,960,748

The LuckyTail annual amortization expense is \$ 532,992 annually and \$44,619 monthly, based on the allocation of the purchase price. For the one and a half months ended September 30, 2022, the proforma adjustment included \$66,624, one and a half months of amortization expense.

The E-Core annual amortization expense is \$1,615,500 annually and \$134,625 monthly, based on the allocation of the purchase price. For the three months ended September 30, 2022, the proforma adjustment included \$403,875 of amortization expense.

External legal, accounting and consulting services directly related to completed acquisitions, due diligence, and review of possible target acquisitions are included in the general and administrative expenses on the Company's condensed consolidated statements of operations.

Note 3. Inventory

Inventory consisted of the following:

	<u>September 30, 2023</u>	<u>June 30, 2023</u>
Raw materials	\$ 1,511,123	\$ -
Finished goods	\$ 12,275,139	\$ 11,557,128
	<u>\$ 13,786,262</u>	<u>\$ 11,557,128</u>

The Company periodically reviews its inventory and makes adjustments to net realizable value, as appropriate.

During the three months ended September 30, 2023 and 2022, the Company wrote off inventory valued at \$ 54,521 and no inventory write off, respectively.

[Table of Contents](#)

Note 4. Property and Equipment

Property and equipment consist of the following:

	September 30, 2023	June 30, 2023
Furniture and fixtures	\$ 212,322	\$ 172,663
Computer equipment	157,634	156,283
Internal use software	634,789	608,949
Manufacturing equipment	3,505,272	3,325,525
Leasehold improvements	75,010	-
Building	5,072,381	4,923,462
Vehicles	295,329	261,362
Property and equipment, gross	9,952,738	9,455,848
Less accumulated depreciation	(2,207,865)	(1,921,780)
	<u>\$ 7,744,873</u>	<u>\$ 7,526,463</u>

Depreciation expense for the three months ended September 30, 2023 and 2022 was \$ 286,084 and \$194,497, respectively.

Note 5. Intangible Assets

Intangible assets as of September 30, 2023:

	Estimated Life	Cost	Accumulated Amortization	Net Book Value
Customer relationships	4 years	\$ 8,243,897	\$ 2,005,602	\$ 6,238,295
Trade name	5 years	2,574,041	1,077,197	1,496,844
Non-compete agreements	Term of agreement	143,000	143,000	-
Online sales channels	2 years	1,800,000	1,350,000	450,000
Vender relationships	5 years	6,000,000	1,800,000	4,200,000
		<u>\$ 18,760,938</u>	<u>\$ 6,375,799</u>	<u>\$ 12,385,139</u>

For the three months ended September 30, 2023 and 2022, the Company amortized approximately \$ 1,186,821 and \$729,909, respectively.

Intangible assets as of June 30, 2023:

	Estimated Life	Cost	Accumulated Amortization	Net Book Value
Customer relationships	4 years	\$ 8,243,897	\$ 1,937,595	\$ 6,306,302
Trade name	5 years	2,574,041	489,341	2,084,700
Non-compete agreements	Term of agreement	143,000	137,042	5,958
Online sales channels	2 years	1,800,000	1,125,000	675,000
Vender relationships	5 years	6,000,000	1,500,000	4,500,000
		<u>\$ 18,760,938</u>	<u>\$ 5,188,978</u>	<u>\$ 13,571,960</u>

Table of Contents

The following intangible assets were added during the year ended June 30, 2023, from the acquisitions noted below:

LuckyTail:

Customer relationships	\$ 1,834,692
Trade name	383,792
Intangible Assets from Purchase	<u>\$ 2,218,484</u>

E-Core:

Customer relationships	\$ 5,080,205
Trade name	1,727,249
Intangible Assets from Purchase	<u>\$ 6,807,454</u>

[Table of Contents](#)

The following intangible assets were added during the year ended June 30, 2022, from the acquisition of VitaMedica, Interactive and Cyngnet.

Customer relationships	\$ 1,329,000
Trade name	463,000
Non-compete agreements	143,000
Online sales channels	1,800,000
Vender relationships	6,000,000
 Intangible Assets from Purchase	 <u>\$ 9,735,000</u>

Future amortization of intangible assets at September 30, 2023 are as follows:

June 30, 2024	\$ 2,736,545
June 30, 2025	3,640,782
June 30, 2026	3,472,032
June 30, 2027	1,503,654
June 30, 2028	840,000
Thereafter	210,000
	<u>\$ 12,403,014</u>

Note 6. Prepaid Expense and Other Current Assets

Prepaid and other current assets consist of the following:

	September 30, 2023	June 30, 2023
Insurance	\$ 161,240	\$ 187,949
Prepayment to vendors	93,143	263,652
Deposits on services	39,047	45,678
Prepaid monthly rent	53,189	27,813
Subscriptions and services being amortized over the service period	111,067	-
Prepaid sales tax		70,021
Other deposits	70,826	70,826
Stock issued for prepaid interest on convertible note payable	350,676	465,595
Other prepaid expenses	78,396	31,000
Other receivables		- 144,765
 Total	 <u>\$ 957,584</u>	 <u>\$ 1,307,299</u>

Note 7. Operating Leases

The Company has operating leases for corporate offices, warehouses and office equipment that have remaining lease terms of 1 year to 5 years.

The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under noncancelable operating leases with terms of more than one year to the total operating lease liabilities recognized in the condensed consolidated balance sheet as of September 30, 2023:

2024	\$ 517,099
2025	619,080
2026	644,121
2027	270,054
2028	244,013
Thereafter	21,115
Total undiscounted future minimum lease payments	2,315,483
Less: Imputed interest	(197,895)
Present value of operating lease obligation	<u>\$ 2,117,588</u>

The Company's weighted average remaining lease term and weighted average discount rate for operating leases as of September 30, 2023 are:

Weighted average remaining lease term	44 Months
Weighted average incremental borrowing rate	5.0%

For the three months ended September 30, 2023, the components of lease expense, included in general and administrative expenses and interest expense in the condensed consolidated statement of operations, are as follows:

	Three Months Ended September 30, 2023
Operating lease cost:	
Operating lease cost	\$ 174,212
Amortization of ROU assets	170,970
Interest expense	26,347
Total lease cost	<u>\$ 371,529</u>

Note 8. Accrued Liabilities

Accrued liabilities consist of the following:

	September 30, 2023	June 30, 2023
Accrued interest	\$ 919,648	\$ 655,187
Accrued vendor liabilities	1,063,841	861,664
Accrued sales tax	37,464	47,070
Accrued expenses from sale of manufacturing operations	1,350,545	1,360,000
Other accrued liabilities	512,924	441,641
	<u>\$ 3,883,841</u>	<u>\$ 3,365,562</u>

[Table of Contents](#)

Note 9. Convertible Promissory Notes and Notes Payable

Convertible promissory notes and notes payable outstanding as of September 30, 2023 and June 30, 2023 are summarized below:

	Maturity Date	September 30, 2023	June 30, 2023
Convertible Notes:			
Promissory Note, 21-month term note, 18.11% interest payable with common stock and subordinate to the Convertible Notes	June 1, 2026	\$ 2,150,000	\$ 2,150,000
Less current portion of notes payable		-	1,254,167
Notes payable, net of current portion		<u>\$ 2,150,000</u>	<u>\$ 895,833</u>
Acquisition Notes:			
Convertible Notes, 36-month term notes, 0% cash interest, collateralized with all the assets of the Company	October 31, 2025	3,500,000	3,500,000
Subordinated Promissory Notes, 24-month term notes, 4% cash interest, collateralized with all the assets of the Company	October 31, 2024	5,750,000	5,750,000
Subordinated Promissory Notes, 12-month term notes, 4% cash interest, collateralized with all the assets of the Company	October 31, 2023	5,750,000	5,750,000
Total		\$ 15,000,000	\$ 15,000,000
Discount on acquisition notes payable, current		(93,380)	(93,380)
Acquisition notes payable, current		5,750,000	5,750,000
Acquisition notes payable, current net		<u>\$ 5,656,620</u>	<u>\$ 5,656,620</u>
Discount on acquisition notes payable, long-term		(1,281,503)	(1,644,915)
Acquisition notes payable, long-term		9,250,000	9,250,000
Acquisition notes payable, long-term net		<u>\$ 7,968,497</u>	<u>\$ 7,605,085</u>
Notes Payable:			
Mortgage Loan, 10-year term note, 4.8% interest, collateralized by land and warehouse building	September 26, 2032	\$ 2,781,193	\$ 2,841,566
Promissory Note, 21-month term note, 10% cash interest and subordinate to the Convertible Notes	November 22, 2024	560,000	560,000
SBA note payable, 30-year term note, 6% interest rate and collateralized with all assets of the Company	October 6, 2021	3,728,970	3,910,767
Inventory consignment note, 60 monthly payments, with first payment due June 30, 2022, 3.5% interest rate and no security interest in the assets of the business	June 30, 2027	1,015,819	1,099,592
GF Note, 6 annual payments, with first payment due December 31, 2022, 3.5% interest rate and no security interest in the assets of the business	November 7, 2026	683,968	683,968
Total notes payable		8,769,950	9,095,893
Discount on notes payable, current		(15,620)	(24,191)
Notes payable, current		4,270,977	2,580,379
Notes payable, current net		<u>\$ 4,255,357</u>	<u>\$ 2,556,188</u>
Discount on notes payable, long-term		(23,522)	(23,522)
Notes payable, long-term		4,498,973	7,769,679
Notes payable, long-term, net		<u>\$ 4,475,451</u>	<u>\$ 7,746,157</u>

Related Notes Payable:

Marshall Loan, 2-year term note, 8.5% cash interest, 3.5% PIK interest and subordinate to the Convertible Notes	June 28, 2024	<u>1,500,000</u>	<u>1,500,000</u>
Discount on related party note payable, long term		(55,507)	(70,644)
Notes payable, long term		<u>1,500,000</u>	<u>1,500,000</u>
Notes payable, long term net		<u>\$ 1,444,493</u>	<u>\$ 1,429,356</u>
Total convertible notes payable, acquisition notes payable, notes payable and related party note payable		<u>\$ 25,950,418</u>	<u>\$ 25,889,239</u>

Future payments on notes payable are as follows:

For the year ended June 30:

	Notes Payable	Convertible Notes	Acquisition Notes Payable	Related Party Note Payable	Total
2024	\$ 4,270,977	\$	\$ 5,750,000	\$	\$ 10,020,977
2025	734,529		5,750,000		6,484,529
2026	1,306,040	2,150,000	3,500,000	1,500,000	8,456,040
2027	627,277				627,277
2028	313,045				313,045
Thereafter	1,518,082				1,518,082
Note original discount	\$ 8,769,950	\$ 2,150,000	\$ 15,000,000	1,500,000	\$ 27,419,950
	(39,142)	-	(1,374,883)	(55,507)	(1,469,532)
	<u>\$ 8,730,808</u>	<u>\$ 2,150,000</u>	<u>\$ 13,625,117</u>	<u>\$ 1,444,493</u>	<u>\$ 25,950,418</u>

Convertible Notes Payable:

In June 2022, the Company entered into a securities purchase agreement with two accredited investors pursuant to which the Company could receive up to \$15,000,000 during the following twelve months of the agreement. The Company received \$ 6,678,506 for Convertible Notes in the original principal amount of \$7,500,000 (the "Convertible Notes"), representing the original purchase amount, less fees, costs and a \$ 500,000 holdback by the investors. In addition to the Convertible Notes, the investors received Common Stock Purchase Warrants (the "Warrants") to acquire an aggregate of 56,250 shares of common stock. The Warrants were exercisable for five years at an exercise price of \$4.44 per share, provide customary anti-dilution protection, and an investor put right to require the Company to redeem the Warrants for a total of \$250,000. There was a loss of \$ 1,770 for the change in the derivative liability for the period ended March 31, 2023. On October 31, 2022, the Company entered into a letter agreement with the accredited investors in which all amounts owed were paid in full and the related convertible notes and all security interests were cancelled. Additionally, the Company terminated the related Form S-3 registration statement.

Table of Contents

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$2,150,000 together with the issuance of 134,000 restricted shares (the "PIK shares") of the Company's common stock at a price of \$ 4.53 per share. The promissory note has a 21-month term and bears interest at 18.11% payable with the PIK shares. The promissory note provides for 12 monthly payments of principal beginning on December 22, 2023, and PIK interest of restricted shares on the Effective Date of the promissory note. The Company shall have the right at any time to convert all or any part of the outstanding and unpaid principal into fully paid and non-assessable shares of common stock, or any shares of capital stock or other securities, together with the PIK shares at a price per conversion share equal to \$5.00.

Acquisition Notes Payable:

On August 1, 2021, the Company entered into a non-negotiable convertible promissory note related to the purchase of VitaMedica in the original principal amount of \$500,000 ("VitaMedica Note"), convertible at \$5.00 per share for a total of 100,000 shares of Company Common Stock. The Company repaid the note in full during August of 2022.

On April 15, 2022, the Company entered into a non-negotiable convertible promissory note in the original principal amount of \$ 1,050,000, as adjusted, ("Cygnet Note") which can be converted into common stock of the Company at a price of \$6.00 per share and is payable in full, to the extent not previously converted, on April 15, 2023. The Company repaid the note in full plus all outstanding accrued interest during April 2023.

The Company and its wholly owned subsidiary, Upexi Enterprises, LLC entered into a securities purchase agreement with E-Core Technology, Inc. d/b/a New England Technology, Inc., a Florida corporation, and its three principals. The Company entered into a series of promissory notes with the principal parties: (a) promissory notes in the total original principal amount of \$5,750,000 payable upon maturity with a term of 12 months at an interest rate of 4%, \$600,000 of which shall be satisfied through the cancellation of an equal amount owed by one of the principals to the Company; (b) promissory notes in the total original principal amount of \$5,750,000 payable upon maturity with a term of 24 months at an interest rate of 4%; and (c) promissory notes in the original principal amounts of \$3,500,000 with a term of 36 months at an interest rate of 0%. The principals may convert the notes into shares of the Company's restricted common stock at a conversion price equal to \$4.81. If the principals do not exercise their conversion rights, the principal balance of the notes will be paid in 12 equal monthly payments commencing on the two-year anniversary of the issuance of the notes, subject to adjustments based on the Company's EBITDA over the term of the notes.

Notes Payable:

In June 2022, the Company executed a promissory note with Allan Marshall, the Company's Chief Executive Officer, in the original principal amount of \$1,500,000 ("Marshall Loan"). The promissory note has a 2-year term and bears cash interest at the rate of 8.5% per annum with an additional PIK of 3.5% per annum. The promissory note provides for monthly payments of principal, on an even line 36-month basis, plus cash interest, with a balloon payment of all outstanding principal, cash interest, and PIK interest at maturity. The Company received and deposited the principal amount on July 31, 2022.

On October 19, 2022, Upexi, Inc. (the "Company") and its indirect wholly owned subsidiary, Upexi 17129 Florida, LLC entered into a loan agreement, promissory note and related agreements with Professional Bank, a Florida state-chartered bank, providing for a mortgage on the Company's principal office in N. Clearwater, Florida. The Company received \$3,000,000 in connection with the transaction. The principal is to be repaid to Professional Bank

over a term of ten years. The proceeds of the loan were utilized by the Company to pay down its loan facility with Acorn Capital, LLC in the amount of \$2,780,200.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$560,000. The promissory note has a 21-month term and bears cash interest at the rate of 10% per annum. The promissory note provides for monthly payments of interest beginning on March 22, 2023 and 12 monthly payments of principal beginning on December 22, 2023.

[Table of Contents](#)

Cygnet Online had certain loans outstanding prior to the acquisition, which continued to be outstanding post acquisition.

- Cygnet Online, entered into a loan for \$4,436,900 with the Small Business Administration. The promissory note has a scheduled payment commencing on November 6, 2021, consisting of principal and interest. The interest rate is adjustable of prime plus 2.5% and is currently at 10.25%. The balance of the principal and interest will be payable ten years from the date of the promissory note.

- Cygnet Online, entered into a 60-month inventory consignment note with the first payment due June 30, 2022. The note bears interest at 3.5% per annum.
- Cygnet Online, executed a promissory note in the amount of \$ 850,000 payable in six annual installments of principal and interest, the final payment due December 1, 2027. The note bears interest at 3.5% per annum.

Line of Credit:

The Company through its wholly owned subsidiary, New England Technology, Inc., maintains a \$ 10,000,000 inventory and accounts receivable line of credit, interest rate of prime minus ½% payable monthly. The outstanding balance at September 30, 2023 was \$118,001 and \$882,845 at June 30, 2023. The availability under the line of credit at September 30, 2023 was \$6,220,013.

Note 10. Related Party Transactions

The Company purchased Interactive Offers, LLC, a Delaware limited liability company in October 2021. The Company's CEO and Chairman, Allan Marshall, is the controlling stockholder and the president of MFA Holdings Corp., which owned 20% of the outstanding membership interests in Interactive.

During the year ended June 30, 2022, the Company entered into a promissory note with a member of management. The loan was for \$ 1,500,000 and has a two-year term with an interest rate of 8.5% per annum with an additional PIK of 3.5% per annum.

Note 11. Equity Transactions

Convertible Preferred Stock

The Company has 500,000 shares of Preferred Stock issued and outstanding to Allan Marshall, CEO. The preferred stock is convertible into the Company's common stock at a ratio of 1.8 shares of preferred stock for a single share of the Company's common stock at the holder's option, has preferential liquidation rights and the preferred stock shall vote together with the common stock as a single class on all matters to which shareholders of the Company are entitled to vote at the rate of ten votes per share of preferred stock.

Common Stock

Subsequent to September 30, 2022, the Company issued 1,247,403 shares of common stock for the acquisition of E-Core Technologies Inc. a Florida corporation, valued at \$6,000,000.

The Company issued 134,000 shares of common stock for prepayment of interest on a note payable. The shares were valued at \$ 607,020 or \$4.52 per common share and recorded as prepaid interest as the shares were issued at that time.

The Company agreed to sell 2,121,213 shares of common stock for a purchase price of approximately \$ 7,000,000. After deducting the underwriter's commissions, discounts, and offering expenses payable by the company, the Company expects to receive net proceeds of approximately \$6,060,000. In addition, the Company issued warrants to purchase approximately 169,000 shares of the Company's common stock at a purchase price of \$ 4.774 per common share.

In September of 2023, the Company issued 90,909 shares of common stock for the purchase of the remaining 45% of Cygnet Online, LLC. The shares were valued at \$162,727 or \$1.79 per common share.

[Table of Contents](#)

Note 12. Stock Based Compensation

The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares. The options are exercisable for a period of up to 10 years from the date of the grant.

The following table reflects the continuity of stock options for the three months ended September 30, 2023:

A summary of stock option activity is as follows:

	Options Outstanding	Weighted Average Exercise Price	Average Remaining Contractual Life (Years)	Aggregated Intrinsic Value
Outstanding at June 30, 2023	4,839,278	\$ 3.31	6.23	\$ 1,342,280
Exercised	-	-	-	-
Forfeited	378,000	\$ 4.34	3.78	
Granted	-	-	-	-
Options outstanding at September 30, 2023	4,461,278	\$ 3.17	6.30	372,856
Options exercisable at September 30, 2023 (vested)	4,099,778	\$ 3.03	6.49	\$ 372,856

Stock-based compensation expense attributable to stock options was \$421,887 and \$927,326 for the three months ended September 30, 2023, and 2022, respectively. As of September 30, 2023, there was \$1,032,725 of unrecognized compensation expense related to unvested stock options outstanding, and the weighted average vesting period for those options was approximately 2 years.

There were no stock options granted during the three months ended September 30, 2023.

There were 4,648,624 shares available for issuance as of September 30, 2023, under the 2019 Plan as amended.

[Table of Contents](#)

Note 13. Income Taxes

The Company computed the year-to-date income tax provision by applying the estimated annual effective tax rate to the year-to-date pre-tax income and adjusted for discrete tax items in the period. The Company's income tax benefit was \$472,367 and \$708,201 for the three months ended September 30, 2023 and September 30, 2022, respectively.

The income tax expense for the three months ended September 30, 2023, was primarily attributable to federal and state income taxes and nondeductible expenses for an effective tax rate of approximately 25.83%. For the three months ended September 30, 2023, the difference between the U.S. statutory rate and the Company's effective tax rate is due to the full valuation allowance on the Company's deferred tax assets.

Future realization of the tax benefits of existing temporary differences and net operating loss carryforwards ultimately depends on the existence of sufficient taxable income within the carryforward period. As of June 30, 2023 and 2022, the Company performed an evaluation to determine whether a valuation allowance was needed. The Company considered all available evidence, both positive and negative, which included the results of operations for the current and preceding years. The Company also considered whether there was any currently available information about future years. The Company determined that it is more likely than not that the Company will have future taxable income. The Company used \$2,506,514 of the federal net operating loss carryover during the year ended June 30, 2022.

As of September 30, 2023, there was approximately \$ 3,097,791 of losses available to reduce federal taxable income in future years and can be carried forward indefinitely.

Note 14. Risks and Uncertainties

There is substantial uncertainty and different interpretations among federal, state and local regulatory agencies, legislators, academics and businesses as to the scope of operation of Farm Bill-compliant hemp programs relative to the emerging regulation of cannabinoids. These different opinions include, but are not limited to, the regulation of cannabinoids by the U.S. Drug Enforcement Administration, or DEA, and/or the FDA and the extent to which manufacturers of products containing Farm Bill-compliant cultivators and processors may engage in interstate commerce. The uncertainties cannot be resolved without further federal, and perhaps even state-level, legislation, regulation or a definitive judicial interpretation of existing legislation and rules. If these uncertainties continue, they may have an adverse effect upon the introduction of our products in different markets.

In December 2019, a novel strain of coronavirus (COVID-19) surfaced. The spread of COVID-19 around the world has caused significant volatility in U.S. and international markets. There is significant uncertainty around the breadth and duration of business disruptions related to COVID-19, as well as its impact on the U.S. and international economies and, as such, the Company has transition to a combination of work from home and social distancing operations and there has been minimal impact to our internal operations from the transition. The Company is unable to determine if there will be a material future impact to its customers' operations and ultimately an impact to the Company's overall revenues.

Note 15. Significant Customers

The Company had significant customers during the three months ended September 30, 2023. A significant customer is defined as one that makes up ten percent or more of total revenues in a particular period or ten percent of outstanding accounts receivable balance as of the period. The Company had no significant customers during the three months ended September 30, 2022.

[Table of Contents](#)

Net revenues for the three months ended September 30, 2023, include revenues from significant customers in the product segment as follows:

	September 30, 2023
Customer A	12.56%

Accounts receivable balances as of September 30, 2023, from significant customers are as follows:

	September 30, 2023
Customer A	22.79%

Note 16. Discontinued Operations – Sale of Infusionz to Bloomios

On October 28, 2022, the Company determined that the best course of action related to Infusionz, LLC and certain manufacturing business was to accept an offer to sell those operations.

The Company received from Bloomios, Inc.(OTCQB:BLMS), the purchaser (i) \$5,500,000 paid at closing; (ii) a convertible secured subordinated promissory note in the original principal amount of \$5,000,000; (iii) 85,000 shares of Series D convertible preferred stock, with a total stated value of \$8,500,000; (iv) a senior secured convertible debenture with a subscription amount of \$4,500,000, after original issue discount of \$779,117; and (v) a common stock purchase warrant to purchase up to 2,853,910 shares of Bloomios's common stock. The Company recorded the consideration received at the estimated value at the time of the transaction and as part of that estimate valued the additional warrants to purchase Bloomios shares of common stock at \$8,500,000 and a valuation allowance of \$8,500,000.

The assets transferred were recorded at their respective book values, the accrued and incurred expenses estimated by management were recorded and the consideration received was recorded at management's estimated fair value based on the balance sheet on October 26, 2022, the effective closing date.

Tangible assets, inventory / working capital*	\$ (1,344,000)
Tangible assets, warehouse and manufacturing equipment, net of accumulated depreciation*	(679,327)
Goodwill	(2,413,814)
Intangible assets, net of accumulated amortization	(946,996)
Accrued and incurred expenses related to the transaction and additional working capital*	(2,051,500)
Consideration received, including cash, debt and equity, net	15,000,000
Total gain recognized	\$ 7,564,363

*During the continuing transition period, all of the inventory or working capital has not been transferred to the buyer.

At closing, the Company provided working capital, in the form of inventory, in excess of the working capital agreement and during the transition period, there are certain expenses and purchases incurred that are to be netted against funds collected on behalf of the buyer. June 30, 2023, there was a receivable balance from the buyer of 845,443, net of a reserve of \$931,613.

Advance for payroll	\$ 50,000
Operating expense	652,891
Management fees	685,600
Excess working capital	388,565
Accrued Interest	247,885
Subtotal due from Bloomios	\$ 2,024,941
 Reserve	 1,179,498
Total due from Bloomios	\$ 845,443

[Table of Contents](#)

For several reasons, including but not limited to the non-payment per the terms of several agreements and the continuous delay in getting the business transitioned, the Company notified Bloomios of its termination of the transition agreement. Management accrued a reserve on the receivable balance of \$1,179,498 leaving a receivable balance of \$845,443 on June 30, 2023. Accrued interest and the gain from the original issue discount were reversed and the remaining balance was expensed to loss from discontinued operations.

During the three months ended, September 30, 2023 the Company recorded the following non-cash amounts against the receivable balance.

Inventory	\$ 1,090,828
Accounts receivable	157,200
Accounts payable and accrued liabilities	(475,817)
Customer deposits	(133,950)
Fixed assets	208,182
Net assets	\$ 845,443
Due from Bloomios	\$ -

Note 16. Discontinued Operations – Sale of Interactive Offers

On August 31, 2023, the Company sold Interactive offers to Amplifyir Inc. The purchase price is \$1,250,000 with a provision to adjust the final purchase price based on the business being transferred to Amplifyir Inc. with a net zero working capital. In addition, the Buyer is obligated to pay the Company two-and one-half percent (2.5%) of certain advertising revenues of Interactive for a two-year period post-closing. Accordingly, the results of the business were classified as discontinued operations in our statements of operations and excluded from both continuing operations and segment results for all periods presented.

Summary of discontinued operations:

	Three months ended September 30,	
	2023	2022
Discontinued Operations		
Revenue	\$ 158,147	\$ 955,762
Cost of sales	\$ 11,982	\$ 730,306
Sales, general and administrative expenses	\$ 339,205	\$ 663,778
Depreciation and amortization	\$ -	\$ 9,795
Income (loss) from discontinued operations	\$ (193,040)	\$ (448,117)
Accounts receivable net of allowance for doubtful accounts	\$ -	\$ 35,482
Fixed assets, net of accumulated depreciation	\$ -	\$ 5,195
Total assets	\$ -	\$ 321,425
Total liabilities	\$ -	\$ 652,911

[Table of Contents](#)

Note 17. Subsequent Events

In June 2022, the Company executed a promissory note with Allan Marshall, the Company's Chief Executive Officer and a Director, in the original principal amount of \$1,500,000. On November 15, 2023, the Company executed an amendment to the promissory note with Mr. Marshall, providing for the payment of interest only for 18 months at an interest rate of 12% per annum and thereafter the amortization of the note over a 12 month period, starting in June of 2025. The principal currently outstanding is \$1,500,000. In addition to this, the Company issued Mr. Marshall a warrant to purchase up to 375,000 shares of the Company's common stock at a per share price of \$ 1.10. The note has been classified as long-term in the financial statements.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$ 560,000. On November 15, 2023, the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12 month period, starting in June of 2025. The principal currently outstanding is \$560,000. In addition to this, the Company issued the investor a warrant to purchase up to 125,000 shares of the Company's common stock at a per share price of \$1.10. The note has been classified as long-term in the financial statements.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$ 2,150,000. In November of 2023, the Company executed an amendment to the promissory note with the investor, providing for the payment of interest only for 18 months at 12% per annum and thereafter the amortization of the note over a 12 month period, starting in June of 2025. The principal currently outstanding is \$2,150,000. In addition to this, the Company issued the investor a warrant to purchase up to 500,000 shares of the Company's common stock at a per share price of \$1.10. The note has been classified as long-term in the financial statements.

On November 2, 2023, the Company paid \$ 2,000,000 of the first acquisition note to the sellers of the E-Core business. \$ 3,750,000 and accrued interest of \$230,000 remain unpaid on this acquisition note. Per the transaction documents, the interest rate on the remaining balance is increased to 12% per annum on the outstanding balance until the debt is paid. Management expects to pay the remaining principal and interest on the note in monthly installments of \$353,618 commencing in December 2023. This loan is classified as current in the financial statements and the other loans with the sellers are unaffected with the default on the first loan.

With the purchase of the remaining 45% of the Cygnet business, the Company was notified that it was in default and the Company would not qualify to refinance Cygent's SBA loan. The SBA presented the Company with a demand notice of \$3,835,975 for all principal and interest due under the SBA loan. The Company is working with the lender to resolve this default and is looking at various options. This loan is classified as current in the financial statements and the other loans to the sellers is unaffected with the default on the loan.

[Table of Contents](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

General Overview

As used in this current report and unless otherwise indicated, the terms "we", "us" and "our" mean Upexi, Inc.

For the three months ended September 30, 2022 the condensed consolidated financial statements of Upexi, Inc. include the accounts of the Company and its wholly-owned subsidiaries; Trunano Labs, Inc., a Nevada corporation, Steam Distribution, LLC, a California limited liability company; One Hit Wonder, Inc., a California corporation; Havz, LLC, d/b/a Steam Wholesale, a California limited liability company, One Hit Wonder Holdings, LLC a California corporation; SWCH LLC, a Delaware limited liability company; Cresco Management LLC, a California limited liability company, and VitaMedica a Nevada corporation, Cygnet Online, LLC a Delaware limited liability corporation and Upexi Pet Products, LLC ("LuckyTail"), a Delaware limited liability corporation as of August 12, 2022.

For the three months ended September 30, 2023, the condensed consolidated financial statements of Upexi, Inc. include all of the subsidiary accounts included in the condensed consolidated financial statements for the three months ended September 30, 2022 and include E-Core Technology, Inc. ("E-Core").

All intercompany accounts and transactions have been eliminated as a result of the consolidation.

Table of Contents

Operating Segments

The Company's financial reporting is organized into two segments: Our Branded Product segment and our Recommerce segment. Our Branded Product segment is focused on the development, growth and distribution of the branded products that we own. Our Recommerce segment is focused on the purchase and sale of new and used products through channels such as Amazon and wholesale distributors. Other sources of revenue and related costs are aggregated and viewed by management as immaterial or have similar economic characteristics, products production, distribution processes and regulatory environment as the other product sales.

Segment Information

The Company provides the following segments: (a) branded product segment and (b) product distribution segment.

For the three months ended September 30, 2023:

	Branded Products	Recommerce	Total
Revenue	\$ 6,562,613	\$ 20,785,029	\$ 27,347,642
Loss from operations	\$ (1,334,082)	\$ 191,928	\$ (1,142,154)
Other (expense)	\$ (842,137)	\$ (32,048)	\$ (874,185)
Depreciation expense	\$ 286,084	\$ -	\$ 286,084
Income tax (expense) benefit	\$ 511,525	\$ (39,158)	\$ 472,367
Segment assets:			
Additions to property, plant, and equipment	\$ 504,495	\$ -	\$ 504,495
Total assets	\$ 35,029,593	\$ 29,743,782	\$ 64,773,375

For the three months ended September 30, 2022:

	Branded Products	Recommerce	Total
--	-----------------------------	-------------------	--------------

Revenue	\$ 3,971,280	\$ 7,247,519	\$ 11,218,799
Loss from operations	\$ (1,965,497)	\$ (411,901)	\$ (2,377,398)
Other (expense)	\$ (427,278)	\$ (4,430)	\$ (431,708)
Depreciation expense	\$ 194,497	\$ -	\$ 194,497
Income tax benefit	\$ 580,725	\$ 127,476	\$ 708,201
Segment assets:			
Additions to property, plant, and equipment	\$ 218,280	\$ -	\$ 218,280
Total assets	<u>\$ 50,056,078</u>	<u>\$ 13,796,989</u>	<u>\$ 63,853,067</u>

[Table of Contents](#)

Results of Operations

The following summary of the Company's operations should be read in conjunction with its unaudited condensed consolidated financial statements for the three months ended September 30, 2023 and 2022, which are included herein.

Three Months Ended September 30, 2023 Compared to Three Months Ended September 30, 2022

September 30,

	2023	2022	Change
Revenue	\$ 27,347,642	\$ 11,218,799	\$ 16,128,843
Cost of revenue	18,639,793	5,401,316	13,238,477
Sales and marketing expenses	2,848,667	1,727,469	1,121,198
Distribution costs	2,850,616	2,127,846	722,770
General and administrative expenses	2,255,928	2,127,846	128,082
Other operating expenses	1,894,792	1,851,732	43,060
Other expenses (income)	874,185	431,708	442,477
Net (loss) income from continuing operations	\$ (1,142,154)	\$ (2,745,520)	\$ 916,765

Revenues increased by \$16,128,843 or 144% to \$27,347,642 compared with revenue of \$11,218,799 in the same period last year. The revenue growth was primarily the result of the acquisition of E-Core and growth in our Brand sales and offset by a slowing of the Recommerce Amazon sales channel. The Company's strategy will continue to focus on the growth of our brands organically and through expansion into additional international markets.

Cost of revenue increased by \$13,238,477 or 245% compared with the same period last year. The cost of revenue increase was primarily related to the acquisition of E-Core's Recommerce business. Gross profit increased by \$2,890,366 compared to the prior year. The combined Recommerce segment only increased \$782,038 while the Brands increased gross profit by over \$2,100,000. Gross margin declined by approximately 20% to 32% as a result of significant increases in the lower margin sales of the Recommerce business segment.

Sales and marketing expenses increased by \$1,121,198 or 65% compared with the same period last year. The increase in sales and marketing expenses was primarily related to the focus on the Brand segment revenue growth and strategic marketing to maximize the return on long-term recurring customer growth.

Distribution costs increased \$722,770 or 34% compared with the same period last year. The increase in distribution costs was primarily related to the overall growth of revenue, however management has implemented several consolidation, repackaging and pricing strategies to continue to reduce the overall distribution costs of our product sales. Management expects the implementation of its initial strategies to be completed by March of 2024.

General and administrative expenses increased by \$128,082 or 6% compared with the same period last year. Management continues to operate the Company efficiently to enable sales growth without significant increases in general and administrative costs.

Other operating expenses increased by \$43,060 or 2% compared with the same period last year. The increase in other operating expenses was primarily related to the amortization of acquired intangible assets, offset by a decrease of the amortization of stock-based compensation.

Table of Contents

During the three months ended September 30, 2023, the Company incurred interest expense of \$874,185 compared to \$453,829 in interest expense incurred during the three months ended September 30, 2022. The increase of interest expense for the three months ended September 30, 2023, was primarily due to the \$363,412 of imputed interest amortization related to acquisitions.

The Company had a net loss from continued operations of \$1,828,755 for the three months ended September 30, 2023 compared to a loss of \$2,745,520 for the three months ended September 30, 2022. The decrease in the net loss from continuing operations is primarily related to the above-mentioned changes.

Liquidity and Capital Resources

Working Capital

	As of September 30, 2023	As of June 30, 2023
Current assets	\$ 24,917,576	\$ 25,455,714
Current liabilities	20,036,817	19,606,010
Working capital	\$ 4,880,759	\$ 5,849,704

Cash Flows

	Three Months Ended September 30,	
	2023	2022
Cash flows used by operating activities – continuing operations	\$ (2,120,290)	\$ (2,516,787)
Cash flows used by investing activities – continuing operations	(648,721)	(2,647,930)
Cash flows (used in) provided by financing activities – continuing operations	(1,082,215)	1,317,814
Cash flows used in operating activities – discontinued operations	(223,957)	(4,240)
Cash flows used by investing activities – discontinued operations	-	-
Cash flows provided (used by) financing activities – discontinued operations	-	-

Net decrease in cash during the period	\$ <u>(4,075,183)</u>	\$ <u>(3,851,143)</u>
--	-----------------------	-----------------------

On September 30, 2023, the Company had cash of \$417,108, a decrease of \$4,492,291 from June 30, 2023.

Net cash from operating activities benefited from non-cash expenses of \$2,273,341, which was used in operating for the growth of accounts receivable of \$2,435,858 and inventory of \$1,138,306 and payment of prepaid expenses and liabilities. The negative cash flow from operations was anticipated by management related to the sales in the first quarter to wholesale and distributors and our purchases of inventory in anticipation of sales growth in the second fiscal quarter. Management anticipates inventory and accounts receivable balances to normalize to historical levels and free up cash flow in January 2024.

Table of Contents

Net cash used in investing activities for the three months ended September 30, 2023 was \$648,721 and was primarily related to the \$500,000 cash used to purchase the remaining 45% ownership of Cygnet and expenses related to the consolidation project to eliminate redundant cost.

Net cash used by financing activities for the three months ended September 30, 2023, was \$1,080,215 compared to cash provided of \$1,317,814 during the three months ended September 30, 2022. The cash used by financing activities was the repayment of \$764,844 on the line of credit and \$317,917 repayment of notes payable.

On October 19, 2022, the Company and its indirect wholly owned subsidiary, Upexi 17129 Florida, LLC entered into a loan agreement with Professional Bank, A Florida state-chartered bank, providing for a mortgage on the Company's principal office in N. Clearwater, Florida. The company received \$3,000,000 in connection with the transaction. The principal is to be paid back to Professional Bank over a term of ten years. The proceeds of the loan

were utilized by the Company to pay down its loan facility with Acorn Capital, LLC in the amount of \$2,780,200, net of fees and other expenses.

On October 31, 2022, Upexi, Inc., paid \$4,275,071 in principal, \$613,466 in accrued interest, \$250,000 for settlement of a Put Option and \$7,900 in miscellaneous fees for a total of \$5,146,437 to the holders of the \$15 million senior secured convertible notes entered into on June 28, 2022. The payment terminates the agreement with the noteholders. The Company also intends to terminate the registration statement covering the senior secured debt.

In June 2022, the Company executed a promissory note with Allan Marshall, the Company's Chief Executive Officer, in the original principal amount of \$1,500,000. On November 15, 2023, the Company executed an amendment to the promissory note with Allan Marshall, the Company's Chief Executive Officer, to pay interest only for 18 months at an interest rate of 12%, per annum and then amortize the note over a 12 month period, starting in June of 2025. The principal outstanding is \$1,500,000. In addition to this, the Company issued Mr. Marshall a warrant to purchase up to 375,000 shares of the Company's common stock at a per share price of \$1.05. The note has been classified as long-term in the financial statements.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$560,000. On November 15, 2023, the Company executed an amendment to the promissory note with an investor to pay interest only for 18 months at cash interest rate of 12%, per annum and then amortize the note over a 12 month period, starting in June of 2025. The principal outstanding is \$560,000. In addition to this, the Company issued the investor a warrant to purchase up to 125,000 shares of the Company's common stock at a per share price of \$1.05. The note has been classified as long-term in the financial statements.

On February 22, 2023, the Company executed a promissory note with an investor, in the original principal amount of \$2,150,000. In November of 2023, the Company executed an amendment to the promissory note with an investor to pay interest only for 18 months at cash interest rate of 12%, per annum and then amortize the note over a 12 month period, starting in June of 2025. The principal outstanding is \$2,150,000. In addition to this, the Company issued the investor a warrant to purchase up to 500,000 shares of the Company's common stock at a per share price of \$1.05. The note has been classified as long-term in the financial statements.

On May 12, 2023, the Company agreed to sell 2,121,213 shares of common for a purchase price of approximately \$7,000,000. After deducting the underwriter's commissions, discounts, and offering expenses payable by the company, the Company expects to receive net proceeds of approximately \$6,060,000. In addition, the Company issued warrants to purchase approximately 169,000 shares of the Company's common stock at a purchase price of \$4.774 per common share.

The Company through its wholly owned subsidiary, New England Technology, Inc., maintains a \$10,000,000 inventory and accounts receivable line of credit, interest rate of prime minus 1/2% payable monthly. The outstanding balance at September 30, 2023 was \$118,001 and \$882,845 at June 30, 2023. The availability under the line of credit at September 30, 2023 was \$6,220,013.

We estimate that we will have sufficient working capital to fund our operations over the twelve months following the date of the issuance of these condensed consolidated financial statements and meet all of our debt obligations.

[Table of Contents](#)

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our senior management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of September 30, 2023 (the "Evaluation Date"). Based on this evaluation, our principal executive officer and principal financial and accounting officer concluded as of the Evaluation Date that our disclosure controls and procedures were not effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission ("SEC") reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive officer and principal financial and accounting officer, as appropriate to allow timely decisions regarding required disclosure. This conclusion is based on findings that constituted material weaknesses. A material weakness is a deficiency, or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company's interim financial statements will not be prevented or detected on a timely basis.

Table of Contents

In performing the above-referenced assessment, our management identified the following material weaknesses:

- (i) inadequate segregation of duties consistent with control objectives; and
- (ii) lack of multiple levels of supervision and review.

We believe the weaknesses and their related risks are not uncommon in a company of our size because of the limitations in the size and number of staff. Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible. However, we plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we plan to implement the appointment of additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls to address such inadequacies, by the end of our 2024 fiscal year as resources allow.

We are currently reviewing our disclosure controls and procedures related to these material weaknesses and expect to implement changes in the current fiscal year, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to potentially mitigate these material weaknesses.

We are currently reviewing our disclosure controls and procedures related to these material weaknesses and expect to implement changes in the current fiscal year, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to potentially mitigate these material weaknesses.

Our management will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal controls over financial reporting (as defined in Rules 12a-15(f) and 15d-15(f) under Exchange Act) that occurred during the quarter ended September 30, 2023, that have materially or are reasonably likely to materially affect, our internal controls over financial reporting. The Company has added significant qualified resources to ensure proper segregation of duties and proper review of the financial reporting policies and procedures.

[Table of Contents](#)

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company may become involved in litigation relating to claims arising out of its operations in the normal course of business. The Company is not involved in any pending legal proceeding or litigation, and, to the best of its knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of its properties is subject, which would reasonably be likely to have a material adverse effect on the Company.

Item 1A. Risk Factors

As a "smaller reporting company", the Company is not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

All of the securities issued by the Company were issued pursuant to the exemption for transactions by an issuer not involved in any public offering under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder and corresponding state securities laws. For more information regarding securities issued, see the Liquidity and Capital Resources section to our Unaudited Condensed Consolidated Financial Statements included herein.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

Exhibit Number	Description
<u>31.1*</u>	<u>Certification of Principal Executive Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934</u>
<u>31.2*</u>	<u>Certification of Principal Financial Officer, pursuant to Rule 13a-14a and 15-d-14a of the Securities Exchange Act of 1934</u>
<u>32.1*</u>	<u>Certification of Principal Executive Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
<u>32.2*</u>	<u>Certification of Principal Financial Officer, pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</u>
101**	Interactive Data File
101.INS	Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

* Filed herewith.

** Furnished herewith.

[Table of Contents](#)

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

UPEXI, INC.

Dated: November 20, 2023

/s/ Allan Marshall

Allan Marshall

President, Chief Executive Officer, and Director
(Principal Executive Officer)

Dated: November 20, 2023

/s/ Andrew J. Norstrud

Andrew J. Norstrud

Chief Financial Officer
(Principal Financial Officer and Principal Accounting
Officer)

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Allan Marshall, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Upexi, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 20, 2023

/s/ Allan Marshall

Allan Marshall,
President, Chief Executive Officer and Director
(Principal Executive Officer)

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew J. Norstrud, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Upexi, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 20, 2023

/s/ Andrew J. Norstrud

Andrew J. Norstrud,
Chief Financial Officer
(Principal Financial Officer and Principal Accounting
Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Allan Marshall, President and Chief Executive Officer of Upexi, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- (1) the quarterly report on Form 10-Q of Upexi, Inc. for the period ended September 30, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Upexi, Inc.

Dated: November 20, 2023

/s/ Allan Marshall

Allan Marshall
President, Chief Executive Officer and Director
(Principal Executive Officer)

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Andrew J. Norstrud, Chief Financial Officer of Upexi, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

- (1) the quarterly report on Form 10-Q of Upexi, Inc. for the period ended September 30, 2023 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Upexi, Inc.

Dated: November 20, 2023

/s/ Andrew J. Norstrud

Andrew J. Norstrud,
Chief Financial Officer
(Principal Financial Officer and Principal Accounting
Officer)